J Am Coll Cardiol. 2010;55:2556 2566. 187. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS; Jneid H, Ettinger SM, Ganiats TG, Lincoff AM, Philippides GJ, Zidar JP; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA fo- cused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e663 e828. 188. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell infarto Miocardico. Lancet. 1994;343:1115 1122. 189. ISIS-4: randomized factorial trial assessing early oral captopril, oral mo- nonitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction: ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669 685. 190. O Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, WooYJ, Zhao DX; ACCF/AHA Task Force. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529 555. 191. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, II: unstable angina, heart failure, primary preven- tion with aspirin, and risk factor reduction. JAMA. 1988;260:2259 2263. 192. Randomised trial of intravenous atenolol among 16 027 cases of sus- pected acute myocardial infarction: ISIS-1: First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57 66. 193. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial: the TIMI Study Group. N Engl J Med. 1989;320:618 627. 194. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, Xie JX, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo- controlled trial. Lancet. 2005;366:1622 1632. 195. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non- ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for The Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148 e304. 196. Andrus MR, Holloway KP, Clark DB. Use of beta-blockers in patients with COPD. Ann Pharmacother. 2004;38:142 145. 197. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005:CD003566. 198. Early treatment of unstable angina in the coronary care unit: a ran- domised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both: re- port of the Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Br Heart J. 1986;56:400 413. 199. Verapamil in acute myocardial infarction: the Danish Multicenter Study Group on Verapamil in Myocardial Infarction. Eur Heart J. 1984;5:516 528. 200. Hansen JF. Treatment with verapamil after an acute myocardial in- farction: a review of the Danish Studies on Verapamil in Myocardial Infarction (DAVIT I and II). Drugs. 1991;42(suppl 2):43 53. 201. Hansen JF, Tingsted L, Rasmussen V, Madsen JK, Jespersen CM. Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction. Am J Cardiol. 1996;77:16D 21D. 202. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling fol- lowing acute myocardial infarction: mechanisms and management. Am J Cardiol. 1991;68:1D 6D. 203. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet. 1995;345:686 687. 204. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials: ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97:2202 2212. 205. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure: the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 206. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the an- giotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333:1670 1676. 207. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publica- tion of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543 551. 208. Katz JN, Gore JM, Amin A, Anderson FA, Dasta JF, Ferguson JJ, Kleinschmidt K, Mayer SA, Multz AS, Peacock WF, Peterson E, Pollack C, Sung GY, Shorr A, Varon J, Wyman A, Emery LA, Granger CB; STAT Investigators. Practice patterns, outcomes, and end-organ dysfunction for patients with acute severe hypertension: the Studying the Treatment of Acute Hypertension (STAT) Registry. Am Heart J. 2009;158:599 606.e1. 209. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. 2009 Focused update in- corporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391 e479. 210. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP;ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, de- sign, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209 216. 211. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Inge PJ, Mehra MR, O Connor CM, Reynolds D, Walsh MN, Yancy CW. Improving evidence-based care for heart fail- ure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122:585 596. 212. O Connor CM, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, Lee KL, Califf RM, Jones RH. Comparison of coro- nary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experi- ence from the Duke Cardiovascular Disease Databank). Am J Cardiol. 2002;90:101 107. 213. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121(pt 1):951 957. 214. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural his- tory of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441 1446. 215. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomy- opathy of the elderly. N Engl J Med. 1985;312:277 283. 216. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure: mechanisms and management. Ann Intern Med. 1992;117:502 510. hypertension to congestive heart failure. JAMA. 1996;275:1557 1562. 218. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med. 2001;249:253 261. 219. Kostis JB, Davis BR, Cutler J, Grimm RH Jr, Berge KG, Cohen JD, Lacy CR, Perry HM Jr, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension: SHEP Cooperative Research Group. JAMA. 1997;278:212 216. 220. Felker GM, Adams KF Jr, Konstam MA, O Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classifi- cation, and risk stratification. Am Heart J. 2003;145(suppl):S18 S25. 221. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, Redfield MM. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 1999;159:29 34. 222. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214 1218. 223. Diez J, Fortuno MA, Ravassa S. Apoptosis in hypertensive heart disease. Curr Opin Cardiol. 1998;13:317 325. 224. Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004;43:2207 2215. 225. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327 334. 226. Shapiro BP, Owan TE, Mohammed S, Kruger M, Linke WA, Burnett JC Jr, Redfield MM. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction. Hypertension. 2008;51:289 295. 227. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metallopro- teinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structur- al, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089 2096. 228. Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, Aranda JM Jr, Abraham WT, Smart FW, Stevenson LW, Kueffer FJ, Bourge RC. Transition from chronic compensated to acute decompen- sated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433 1441. 229. Melenovsky V, Borlaug BA, Rosen B, Hay I, Ferruci L, Morell CH, Lakatta EG, Najjar SS, Kass DA. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ven- tricular hypertrophy in the urban Baltimore community: the role of atrial remodeling/dysfunction. J Am Coll Cardiol. 2007;49:198 207. 230. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular-vascular func- tion in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation. 2007;115:1982 1990. 231. Borlaug BA, Lam CS, Roger VL, Rodeheffer RJ, Redfield MM. Contractility and ventricular systolic stiffening in hypertensive heart dis- ease insights into the pathogenesis of heart failure with preserved ejec- tion fraction. J Am Coll Cardiol. 2009;54:410 418. 232. Kramer K, Kirkman P, Kitzman D, Little WC. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revas- cularization. Am Heart J. 2000;140:451 455. 233. Goldberger JJ, Peled HB, Stroh JA, Cohen MN, FrishmanWH. Prognostic factors in acute pulmonary edema. Arch Intern Med. 1986;146:489 493. 234. Clark LT, Garfein OB, Dwyer EM Jr. Acute pulmonary edema due to ischemic heart disease without accompanying myocardial infarction: natural history and clinical profile. Am J Med. 1983;75:332 336. 235. Dodek A, Kassebaum DG, Bristow JD. Pulmonary edema in coronary- artery disease without cardiomegaly: paradox of the stiff heart. N Eng J Med. 1972;286:1347 1350. 236. Chin MH, Goldman L. Correlates of major complications or death in pa- tients admitted to the hospital with congestive heart failure. Arch Intern Med. 1996;156:1814 1820. 237. Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P. Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension. 1996;27:144 147. 238. Belardinelli R, Georgiou D, Purcaro A. Low dose dobutamine echocar- diography predicts improvement in functional capacity after exercise training in patients with ischemic cardiomyopathy: prognostic implica- tion. J Am Coll Cardiol. 1998;31:1027 1034. 239. Specchia G, De Servi S, Scire A, Assandri J, Berzuini C, Angoli L, La Rovere MT, Cobelli F. Interaction between exercise training and ejec- tion fraction in predicting prognosis after a first myocardial infarction. Circulation. 1996;94:978 982. 240. O Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pina IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1439 1450. 241. Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O Connor CM, Weinfurt KP; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart fail- ure: HF-ACTION randomized controlled trial. JAMA. 2009;301:1451 1459. 242. Fletcher GF, Balady GJ, Amsterdam EA, Chaitman B, Eckel R, Fleg J, Froelicher VF, Leon AS, Pina IL, Rodney R, Simons-Morton DA, Williams MA, Bazzarre T. Exercise standards for testing and train- ing: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:1694 1740. 243. Shephard RJ, Balady GJ. Exercise as cardiovascular therapy. Circulation. 1999;99:963 972. 244. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305 1315. 245. Neuberg GW, Miller AB, O Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M; PRAISE Investigators, Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart fail- ure. Am Heart J. 2002;144:31 38. 246. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med. 1985;103:1 6. 247. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introduc- ing diuretics. Br Heart J. 1987;57:17 22. 248. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O Connor CM; NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797 805. 249. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structureandfunctioninpatientswithleftventriculardysfunction:resultsof the SOLVD echocardiography substudy. Circulation. 1995;91:2573 2581. 250. Longobardi G, Ferrara N, Furgi G, Abete P, Rengo F. Improvement of myocardial blood flow to ischemic regions by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2000;36:1437 1438. 251. Leesar MA, Jneid H, Tang XL, Bolli R. Pretreatment with intracoronary enalaprilat protects human myocardium during percutaneous coronary angioplasty. J Am Coll Cardiol. 2007;49:1607 1610. 252. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, Kinoshita M. Bradykinin stimulates the release of tissue plasminogen ac- tivator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37:1565 1570. 253. Gustafsson F, Torp-Pedersen C, Kober L, Hildebrandt P. Effect of angio- tensin converting enzyme inhibition after acute myocardial infarction in Rosendorff et al Treatment of Hypertension in Patients With CAD 1407 patients with arterial hypertension: TRACE Study Group, Trandolapril Cardiac Event. J Hypertens. 1997;15:793 798. 254. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisin- opril, on morbidity and mortality in chronic heart failure: Atlas Study Group. Circulation. 1999;100:2312 2318. 255. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in pa- tientswithtype2diabetesandnephropathy.NEnglJMed.2001;345:861 869. 256. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM,LocatelliF,GoldhaberSZ,LewisEJ;CollaborativeStudyGroup.Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170 2179. 257. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582 1587. 258. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A ran- domized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667 1675. 259. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin- converting-enzyme inhibitors: the CHARM-Alternative Trial. Lancet. 2003;362:772 776. 260. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777 781. 261. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362:759 766. 262. White HD. Candesartan and heart failure: the allure of CHARM. Lancet. 2003;362:754 755. Olofsson B,Yusuf S, Pfeffer MA; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767 771. 264. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/ XL Randomised Intervention Trial in Congestive Heart Failure (MERIT- HF). Lancet. 1999;353:2001 2007. 265. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651 1658. 266. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann- Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the mor- bidityofpatientswithseverechronicheartfailure:resultsoftheCarvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002;106:2194 2199. 267. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S,Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation. 1996;94:2807 2816. 268. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, B hm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215 225. 269. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, ScherhagA,SkeneA;CarvedilolOrMetoprololEuropeanTrialInvestigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7 13. 270. Taylor AL, Ziesche S, Yancy C, Carson P, D Agostino R, Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African- American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049 2057. 271. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the manage- ment of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:1810 1852. 272. Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Hydralazine for essential hypertension. Cochrane Database Syst Rev. 2011:CD004934. M,Young WF Jr, MontoriVM; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrin Metab. 2008;93:3266 3281. 274. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hyperten- sion: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275 1281. 275. SYMPLICITY HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic de- nervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903 1909. 276. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Bohm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hy- pertrophy and improves cardiac function in patients with resistant hyper- tension. J Am Coll Cardiol. 2012;59:901 909. 277. Bhatt DL, Kandzari DE, O Neill WW, D Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha- Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393 1401. 278. Moss AJ, Oakes D, Benhorin J, Carleen E. The interaction between diltiazem and left ventricular function after myocardial infarction: Multicenter Diltiazem Post-Infarction Research Group. Circulation. 1989;80(suppl):IV102 IV106. 279. O Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, Wertheimer JH, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE Trial: Prospective Randomized Amlodipine Survival Evaluation. Am J Cardiol. 1998;82:881 887. 280. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, Cintron G, Boden W, Baruch L, Rochin P, Loss L. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HEFT III: Vasodilator-Heart Failure Trial (V-HEFT) Study Group. Circulation. 1997;96:856 863. 281. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C,Wright TJ; MOXCON Investigators.Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in pa- tients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659 667. 282. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: theAntihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALLHAT Collaborative Research Group. JAMA. 2000;283:1967 1975. 283. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflamma- tory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121:289 300. 284. WheltonA. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physi- ologic foundations and clinical implications. Am J Med. 1999;106:13S 24S. Key Words: AHA Scientific Statements blood pressure coronary artery disease epidemiology hypertension secondary prevention